ImmunoGen’s First ADC For Ovarian Cancer To Exceed Sales Expectations
Stellar Launch For Elahere
Executive Summary
ImmunoGen’s Elahere, the only antibody-drug conjugate approved for platinum-resistant ovarian cancer in the US, will produce better than anticipated sales for the first quarter of 2023, CEO Mark Enyedy hinted in a recent interview.
You may also be interested in...
Finance Watch: Lucky Few Raise Cash While Many Public Biotechs Cut Costs
Public Company Edition: ImmunoGen received the first $75m under a $175m term loan, while Protagonist raised $100m in a follow-on offering, but companies with bankruptcy filings and job cuts outpaced those accessing new capital by a wide margin in late March and early April.
ADCs Coming Of Age: Deals, Targets And Catalysts
The antibody-drug conjugate field is beginning to reach its full potential and big pharma’s attention has been caught.
Keeping Track: Early Thanks Given By ImmunoGen, Provention Bio; More PD-1/L1 Combo Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker